Evaluation of Dissolution Profiles of a Newly Developed Solid Oral Immediate-Release Formula Containing Alpha-Lipoic Acid

Anca Lucia Pop 1, Simona Crisan 2, Maria Barca 1, Anne-Marie Ciobanu 1, Valentin Nicolae Varlas 3,*, Coriolan Pop 2, Mariana-Ana Pali 2, Dumitru Cauni 2, Emma Adriana Ozon 1,* Denisa Udeanu 1, Simona Trifu 4 and Bogdana Adriana Nasiu 5

1 Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, 6 Traian Vui Street, 020945 Bucharest, Romania; ancapop@hotmail.com or anca.pop@umfcd.ro (A.L.P.); maria.barca@umfcd.ro (M.B.); anne.ciobanu@umfcd.ro (A.-M.C.); denisa.udeanu@umfcd.ro (D.U.)
2 R&D Center, AC HELCOR, Victor Babes St., 430082 Baia Mare, Romania; simona.crisan@achelcor.ro (S.C.); coriolan.pop@achelcor.ro (C.P.); mariana.pali@achelcor.ro (M.-A.P.); dumitru.cauni@achelcor.ro (D.C.)
3 Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 030167 Bucharest, Romania
4 Department of Clinical Neurosciences, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu St., 020021 Bucharest, Romania; simona.trifu@umfcd.ro
5 Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 6 Louis Pasteur Street, 400349 Cluj-Napoca, Romania; adriana.nasui@umfcluj.ro
* Correspondence: dr.valentinvarlas@gmail.com or varlas.valentin@umfcd.ro (V.N.V.);
emma.budura@umfcd.ro (E.A.O.); Tel.: +40-72-222-9561

Abstract: Alpha-lipoic acid (ALA, thioctic acid), a naturally-occurring essential dithiol compound, has become a common ingredient in many pharmaceutical and food supplement products (FSP), used in oxidative stress-dependent pathologies; oral bioavailability of ALA is limited by pharmacokinetic particularities that reduce its therapeutic efficacy-reduced solubility, lack of gastric stability and hepatic degradation, doubled by formulation hinders. The objectives were to develop a solid oral 600 mg ALA FSP to obtain an optimal pharmaceutical profile compared to a reference listed drug (RLD) with a similarity factor f2 > 50. A comparative dissolution study was performed; an HPLC method was used for ALA quantification. After planning combinatorial simulations (formulation stage), two prototype formulas (#1 and #2) were manufactured and further optimized by adjusting ALA physical characteristics and the excipients quantities (#3 and #4) in order to achieve the Quality Target Product Profile. A missmatch of ALA’s in vitro release was observed for #3 Formula (f2 = 31.6); the optimal formula was obtained for Formula #4 (f2 = 58.5). A simple quantitative formula is not enough to assure good ALA bioavailability; the formulation needs multiple compounding modulations under physicochemical compatibility algorithms, with multiple dissolution profiles testing back-ups. It is essential to ensure a formulation with an in vitro dissolution comparable with the RLD, allowing the compound to reach its target level to assure the optimum claimed antioxidant activity of ALA at the cellular level, even for food supplement formulations.

Keywords: alpha-lipoic acid; tablets; dissolution rate; formulation effect; dissolution profiles; food supplements; quality target product profile

1. Introduction

The lipoic acid (α-lipoic acid, alpha-lipoic acid, thioctic acid, ALA, LA, Synonym: (±)-1,2-Dithiolane-3-pentanoic acid, 6,8-Dithiooctanoic acid, DL-α-Lipoic acid, DL-6,8-Thiocetic acid, Lip (S2), Thioctic acid) (CAS number: 1200-22-2) [1] is an eight-carbon organosulfur fatty acid derived from caprylic acid (octanoic acid). ALA is synthesized in trace quantities in animals, found in microorganisms, plants, and animals [2,3]; humans obtain ALA via de novo mitochondrial synthesis or from food [4,5] animal-derived (red meat, liver, heart, ...
and kidney) or plants (spinach, broccoli, tomatoes, Brussel’s sprouts, potatoes, garden peas, and rice bran) [6,7]. ALA functions in the body, much like a B-vitamin. It is an essential cofactor in the mitochondrial aerobic metabolism and multienzyme complexes, being implied in the glucose conversion and energy production [8] and a potent antioxidant [9–11]. ALA displaying an excellent scavenging activity against the hydroxyl radical (HO·), with anti-inflammatory activity—by decreasing the tumor necrosis factor (TNF)-α, interleukin (IL)-1 beta (IL-1β), and IL-6 [12,13], performing an anti-aging activity [14] metal-chelating capacities and acting on the second messenger nuclear factor κB without any side effects [15]; almost meets all standards of a perfect anti-aging substance [15]. Consequently, the widespread use of ALA as a functional compound is increasing [16].

The alpha-lipoic acid is present in two forms, reduced and oxidized (DHLA); it has an intramolecular disulfide bond (at C6 and C8) in its oxidized form (Figure 1). ALA is a cofactor for several enzymes, including pyruvate dehydrogenase complex (PDH; EC) and α-ketoglutarate dehydrogenase complex (KDH; EC), two enzymes located in mitochondria and involved in energy production [17].

![Figure 1](image_url)

**Figure 1.** (a) Structure of RS α-Lipoic acid, (±)-1,2-Dithiolane-3-pentanoic acid, 6,8-Dithiooctanoic acid, DL-α-Lipoic acid, DL-6,8-Thioctic acid, Lip(S2) (DHLA) (b) Conversion of ATP to ADP [18].

ALA has two enantiomers: R-(+)-lipoic acid (R-(+)-LA and S-(−)-lipoic acid (S-(−)-LA). The naturally occurring form of ALA is the R-(+)-enantiomer, acting as an essential cofactor of the mitochondrial pyruvate dehydrogenase multienzyme complex [19,20]; due to the high electron density of 1,2-dithiolane ring, it has a high tendency for reduction of other redox-sensitive molecules [21].

ALA is hydro and lipo-soluble, being the only antioxidant to be simultaneously dissolved in the fat and water solutions [22,23]; according to the Biopharmaceutics Classification System (BCS), ALA is found in BCS II [24].

ALA is unstable under light or heat; polymerization occurs readily when the temperature is close to or higher than the melting point (58.6 °C); an unpleasant odor accompanies its decomposition.

After oral administration ALA passes the intestinal mucosa in a pH-dependent manner [25] and then is transported to the intracellular compartments; further on, it is reduced to dihydrolipoic acid (DHLA) under the action of enzymes.

ALA has reduced in vivo solubility, lacks gastric stability, and underpasses hepatic degradation, generating a bioavailability of around 30% and a short half-life [26]. The absorption of ALA is reduced with meals; ALA passes the blood–brain barrier [27].

ALA is marketed as a drug but also as a food supplement. alpha-lipoic acid is present on the European medicine market under different oral formulations such as film-coated
tablets (THIOCTACID 600 HR, Thiossen 600 mg, authorized and marketed in Romanian and Alpha Lipon Aristo® 600 mg authorized and marketed in Germany), soft capsules (Alpan® 300 mg, alpha-RP 600 mg and alpha-Vibolex 600 HRK—all three products being authorized and marketed in Germany) and hard capsules (alpha-MIP 200 and alpha-RP 200 mg, being marketed in Germany).

Several patents on lipoic acid were submitted during the last years, i.e., one of the first methods comprising administering an effective amount of DL-(+−)–α-lipoic acid, D-(+)-α-lipoic acid, and/or L-(−)-α-lipoic acid is reduced or oxidized form or a tromethamol salt thereof, the patent expired [28]; other newer modulations on the active ingredient as alpha-lipoic acid/cyclodextrin complex [29], alpha-lipoic acid-including capsule, with a film containing a natural pigment and a caramel pigment [30], alone or in antioxidant as combinations with alpha-lipoic acid, phytoene, D-biotin, coenzyme Q10, α-glucosylrutin, carnitine, camosine, isoflavonoids, creatine, taurine, and β-alanine [31] and others. ALA hybrids with various activities pharmacophores possess enormous therapeutic potential but need support by reliable in vivo and clinical trials, backed up by consistent formulations to surpass the bioavailability hindrances [32].

However, as the regulations do not compel, a series of oral ALA forms as food supplements may not fulfill the stability and bioavailability tests and standards. Formulating a stable, bioavailable oral form is a complicated task requiring a rigorous choice of excipients and controlled pharmacokinetics. A precise formulation of ALA backed by in vitro dissolution tests is essential even as a food supplement.

1.1. Clinical Pharmacology

ALA is a well-established treatment for neuropathic symptoms and dysfunctions in distal symmetric polyneuropathy (DSP) and type 2 diabetes [33,34].

The neuroprotective properties of ALA in diabetes are considered to result from various mechanisms, including protection against excessive oxidative stress, restoration of glutathione levels, improvement of insulin-stimulated glucose disposal, enhancement of nerve blood flow, and protection against protein glycation [35]. ALA generates an improvement in insulin sensitivity and whole-body glucose metabolism in patients with type 2 diabetes [36,37].

ALA is involved in the intracellular process of converting glucose into ATP—a form of energy that the body can use; it has antioxidant action, both in hydrophilic and hydrophobic environments, in both forms: Reduced and oxidized. ALA improves diabetes-related diseases as diabetic neuropathy (first used in Germany) and regulates the triglyceride levels in obesity.

A recent meta-analysis showed that ALA decreased leptin and increased adiponectin -duration of intervention for more than eight weeks [38]. In an in vitro model using human fetal membranes, α-lipoic acid inhibited inflammation-induced fetal membrane weakening [39]. ALA administration may reduce inflammatory markers such as CRP, IL-6, and TNF-α among patients with MetS and related disorders [40].

1.1.1. ALA in Neurological & Psychiatric Conditions

Recently, ALA showed slower whole brain atrophy in secondary progressive multiple sclerosis, suggesting a neuroprotective effect. Diminishing the retinal nerve fiber layer as detected by optical coherence tomography (OCT) occurs 3–6 months following acute optic neuritis (AON), indicating retinal nerve ganglion cells axonal degeneration. Simultaneously, corticosteroids speed AON recovery, neuroprotective therapies for AON are lacking [41].

LA supplementation significantly reduces TBARS, AOPP, improves TAS levels in healthy subjects, but it showed significant differences in bipolar or schizophrenic patients group [42–44] a need for well-designed clinical trials to enhance the clinical evidence of ALA effects [45].
1.1.2. ALA and Cystinuria

Cystinuria, the recurrent formation of cystine-based kidney stones, with a high frequency of recurrence, often requiring repetitive surgical interventions to remove large stones [46], is caused by mutations in the SLC3A1 and/or SLC7A9 gene(s) [47]. Lipoic acid and derivatives can prevent or slow the development of cystine kidney stones [48].

1.1.3. ALA in PCOS

High-mobility-group-box-1 (HMGB1) was shown to increase in polycystic ovary syndrome (PCOS) due to reduced cystic-fibrosis-transmembrane-conductance-regulator (CFTR) expression in the ovary, associated with insulin resistance and inflammation. Inositols and ALA derivatives could positively affect insulin sensitivity, reduce androgens, and improve ovulation rhythm enhancing fertility and reducing pelvic pain in endometriosis [49,50]. ALA supplementation has been traditionally used in pregnant women with peripheral neuropathy [51]; used for six weeks postpartum in women after primary C-section with hysterotomy closure improved the healing process and decreased the C-section scar defects [52].

1.1.4. ALA and Cancer

ALA reduces chemotherapy side effects having a substantial role in potentiating and synergizing the cytotoxic effect of antineoplastic agents while protecting normal body tissue, increasing patient survivability [53]. ALA's anti-proliferative effect on tumor cells is due to the increased reduction in epidermal growth factor receptor expression ErbB2 and ErbB3 [54].

Caspases are photolytic proteins that induce intrinsic and programmed cell death [55,56]; ALA can affect downstream targets of the photolytic protein caspases on cancer cells. i.e., on caspase-3 in breast cancer and neuroblastoma cell lines, ALA plays a key role in increasing p27, p21, and p53 protein expressions that mediate cell cycle arrest and apoptosis by triggering caspase-3 activity [57,58]. ALA down-regulates the anti-apoptotic protein Mcl-1, Bcl-xL, and the epithelial-mesenchymal transition proteins in breast cancer cells [59–61]; ALA can significantly decrease tumor size in an animal model [62]. Increased ROS production is generated in cancer cell progression by an increased cell turnover, altered metabolic activity, and malfunction of intrinsic antioxidants [63]. ALA induces autophagy via inhibition of O 6-methylguanine-DNA methyltransferase (MGMT) protein, which leads to apoptosis and cytotoxicity chemo-resistant colorectal cancer cells [64,65].

The antioxidant effects of ascorbic acid and liposomal ALA as an adjuvant in cancer treatment were recently re-stated [66–68] in ovarian carcinoma cells [69], human breast cells [70,71], non-small lung cancer cells [72], human colon cancer cells [73] or hepatoma cells [74].

1.1.5. ALA and COVID19

Serum and tissue lactate levels increase in patients with critically ill COVID-19. Since tissues’ oxygenation is insufficient in patients with COVID-19, a hypoxic environment occurs [2,16,75,76].

Increasing the antioxidants levels by ALA may provide an initial defensive mechanism against COVID-19 [76]. Zhang et al. [77] administered 1200 mg ALA therapy to 17 patients with critically ill COVID-19. After 30 days of follow-up, the mortality rate was reported two-fold lower in the ALA group than in the placebo group. ALA reduces the ADAM17 activation and its effect by inhibiting NADPH oxidase activity. ALA can reduce the viral load by preventing ACE2 upregulation [78].

ALA treatment increases intracellular pH and AOX levels, reducing oxidative stress and preventing tissue and cell damage by decreasing lactate production. ALA may strengthen the human host defense in SARS-CoV-2 infection; used with insulin in pa-
Patients with diabetes can have a synergistic effect against SARS-CoV-2 and can play a vital role in critically ill COVID-19 patient treatment.

1.2. Pharmacokinetics

The lipoic acid and or lipoic acid derivatives can be administered in the “native” form or as salts, esters, amides, prodrugs, derivatives that can be prepared using standard procedures described by Advanced Organic Chemistry (2007) [79].

The lipoic acid and or lipoic acid derivative(s) are useful for parenteral administration, topical administration, oral administration, nasal administration (or otherwise inhaled), rectal administration, or local administration, by aerosol or transdermal, for prophylactic and or treatment of one or more of the pathologies (e.g., pathologies characterized by excess amyloid plaque formation and deposition or undesired amyloid or pre-amyloid processing).

Increasing bioavailability of (R)-alpha-lipoic acid boosts antioxidant activity in the treatment of neuropathic pain.

The activity of the ALA molecule is limited by two critical factors: (i) The low stability to oxidation and heat (ii) and the low solubility [80].

1.3. Study Objectives

We aimed to elaborate a qualitative food supplement product based on alfa lipoic acid, 600 mg per tablet strength, with oral administration and immediate release by performing the pharmaceutical development considering technological and bioavailability aspects-compared to the reference product. Consequently, the objectives of the present study were (a) to develop a reliable oral formula of food supplement product (FSP) thioctic acid by a Quality by Design approach (QbD) and (b) to test the quality of the obtained product with the rigorousness of a drug product testing, in order to assure an optimal pharmaceutical profile of thioctic acid FSP compared to the reference listed drug (RLD) with a similarity factor $f_2$ above 50.

2. Materials and Methods

2.1. Materials:

Characteristic of ingredients used in the studies:

1. Alpha-lipoic acid (Azienda Chimica e Farmaceutica, Italy, batch no. Q075302);
2. Alpha-lipoic acid reference listed drug (RLD-Thiossen 600 HR; Dragenopharm Apotheke Püschl GmbH, Germania; batch number 160053).
3. Sodium Carboxymethylcellulose (JRS Pharma GmbH&co. KG, Rosenberg, Germany, batch no. 71118010031)
4. Magnesium stearate (Mosselman s.a, Ghlin, Belgium, batch no. 414661)
5. Colloidal silicon dioxide (Wacker Chemie AG, Nünchritz, Germany, batch no. YA79686)

All the raw materials complied with the technical specifications (Supplementary Table S1).

2.2. Methods

2.2.1. Methods of Tablets Preparation

The manufacturing process of the tablets is performed in the following stages:

Weighing the ingredients used in the manufacturing process. The necessary ingredients (alpha-lipoic acid, sodium carboxymethylcellulose, magnesium stearate, and colloidal silicon dioxide) needed for the manufacturing of the tablets are weighed according to the weighing instructions, in a room with controlled air conditioning (constant temperature and humidity: $21 \pm 2 ^\circ \text{C}$, respectively 50% ± 10% RH) and in the required amounts.

Homogenization of the ingredients, weighted at a previous stage. The ingredients are homogenized at 70 r.p.m. (homogenizer rotation speed) for 7 min. The homogenous mixture as an intermediate is discharged into a stainless steel container.
The physico-chemical control of the compression mixture—according to the requirements of the Technical Specification with the issuance of a Certificate of Analysis which attests the conformity of the mixture with the specification.

Compression - the ready homogenized powder is compressed into tablets on a rotary compression machine, at the following parameters: Press speed 0–100 rpm; dispenser speed 0–60 rpm.

The physico-chemical control of the tablets is performed according to the requirements of the Technical Specification with the issuance of a Certificate of Analysis, which attests the conformity of the mixture with the specification. The parameters which are checked are appearance, assay, dissolution, and average mass.

2.2.2. Methods of Physicochemical Properties Characterization

Average weight

The testing was done by individually weighing 30 tablets, then calculating the average mass. The tablets comply with the test if not more than one individual mass is outside the limits of 85–115% of the average mass.

Hardness

Tablet hardness was measured with VK 200 Tablet Hardness Tester. A tablet was placed in the hardness tester, and the load required to crush the tablet was registered.

Friability

The initial weight of 10 tablets is taken, and these are placed in the Vankel friablator, rotating at 25 rpm for four minutes, then weighed again. The difference in the weight is noted and expressed as a percentage. It should be preferably below 1.0%.

Quantitative Determination of ALA by HPLC Method

Materials

According to the USP edition in force requirements, the determination of lipoic alpha acid in tablets was carried out by an HPLC method [81,82]. The relative SD for repeated injections of the standard solution was not more than 2.0%; the reagents used were: Bi-distilled water; Acetonitrile; Potassium phosphate; Methanol; Phosphoric acid solution [83,84]. Reference substances: Alpha-lipoic acid (Azienda Chimica e Farmaceutica, Italy).

Experimental tablets

The experimental tablets’ manufacture was done in the R&D Department using the RIVA Piccola® Rotary Tablet Press, Riva® Europe, England. Four experimental formulas were manufactured (Experimental Formula #1; Experimental Formula #2; Experimental Formula #3 and Experimental Formula #4 Batch number S580317/Exp. 03.2019).

HPLC analysis

Apparatus: For the quantitative analysis of the ALA, we used a High-Performance Liquid Chromatographic system (JASCO®, Tokyo, Japan) equipped with the mixt degassing system, UV detector, chromatographic column thermostat chamber, and a Kinetex® HPLC Column, C 8, 250 × 4.6 mm, 5 µm (Phenomenex, batch no. 5708-013).

Mobile phase: Methanol: 0.005 M Phosphate solution: Acetonitrile (1160:920:180), adjust the pH to 3.0–3.1 with the phosphoric acid solution, filter, and degas.

Dilution buffer: 0.005 M Phosphate solution: Acetonitrile (1:1); adjust the pH to 3.5–3.7 with a phosphoric acid solution, filter, and degas.

Chromatographic conditions:

- Column temperature: 350 °C;
- Flow rate: 1.2 mL/min;
- UV detection at 215 nm;
- Injection volume: 20 µL;

Solutions used in the determination:

Standard solution: 50.0 mg alpha-lipoic acid is dissolved in dilution buffer, then diluted with the same solvent to 50 mL (1.0 mg/mL alpha-lipoic acid r.s.);
Tested solution: To 52.5 mg tablet powder corresponding to 50.0 mg alpha-lipoic acid, 25 mL of dilution buffer were added and shaken for 10 min, then diluted with the same solvent to 50 mL. Then filter through a 0.45 um filter.

Calculations:
We calculate the amount of alpha-lipoic acid by Formula (1):

\[
\text{ALA/tablet (mg)} = \frac{\text{Ap} \times \text{Ge} \times M}{\text{Ae} \times \text{Gp}}
\]

Ap— the area of the peak corresponding to the alpha-lipoic acid in the sample solution;
Ge— the weight of the standard, of alpha-lipoic acid w.s./r.s., mg;
Ae— peak area corresponding to alpha-lipoic acid in the standard solution;
Gp— the mass of tablet powder, mg;
M— the average mass of tablets, mg.

The System Suitability
The system suitability was tested on a reference solution (1.024 mg/mL alpha-lipoic acid, n = 6) by the following parameters:

- Retention time (t);
- Number of theoretical plates (N);
- Asymmetry factor (T);
- System precision—relative standard deviation (% RSD) <2% (retention time, peak area).

The selectivity and specificity of the method
In order to demonstrate the selectivity and the specificity of the method, we assessed the influence of the extraction solvent (dilution mixture), the influence of the mobile phase, and the influence of excipients (placebo) in the composition of the product (Table 1) by successively injecting the following solutions into the chromatographic system:

- The placebo solution: 0.06 mg/mL excipients in the dilution mixture;
- The pure Alpha-lipoic acid solution: 1.024 mg/mL alpha-lipoic acid in the dilution mixture;
- The reconstituted 600 mg ALA sample solution: 1.016 mg/mL alpha-lipoic acid and 0.058 mg/mL excipients in the dilution mixture;
- The test formula 600 mg sample solution–tablet, batch number S580317

Table 1. Placebo formula composition (containing excipients).

<table>
<thead>
<tr>
<th>Raw Materials</th>
<th>Quantity, mg/tb. 600 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium carboxymethylcellulose</td>
<td>22.8</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>6.0</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>1.2</td>
</tr>
<tr>
<td>Total</td>
<td>30.0</td>
</tr>
</tbody>
</table>

2.2.3. In Vitro Dissolution Test of Alpha-Lipoic Acid in the Final Dosage Forms
In a Biopharmaceutics Classification System (BCS), orally administered drugs are categorized into four classes depending on the solubility and permeability. BCS class I drugs exhibit high solubility and high permeability, class II drugs low solubility and high permeability, class III drugs high solubility and low permeability, and class IV drugs low solubility and low permeability [85,86]. ALA is found in BSC II [25] and tested according to the USP ALA tablets Monograph.

The dissolution test for alpha-lipoic acid tablets was performed under the following conditions:

- Dissolution apparatus no. 2 USP (paddle);
- Dissolution medium: Water;
• Average dissolution volume: 900 mL;
• Rotational speed: 75 rpm;
• Temperature: 37 ± 0.5 °C;
• Dissolution time: 60 min.

2.3. Statistics

Statistical analysis was performed using Microsoft Excel® 2013 Data Analysis software (Microsoft® Corporation, Redmond, WA, USA). We described the continuous variables using the median (range), mean and standard deviation with a 95% CI or count.

The dissolution testing of immediate-release solid oral dosage forms used the FDA recommended the similarity factor \( f_2 \), which define the distance between the dissolution curves for two products, reference, and test [87]:

\[
f_2 = 50 \log \left( 1 + \frac{\sum_{i=1}^{p} (\mu_{ri} - \mu_{ti})^2}{p} \right)^{-1/2} \times 100.
\] (2)

\( \mu_{ri} \) and \( \mu_{ti} \) are means of the population of results at time \( t_i \) for the reference and tested products and \( p \) the size of the population, by the estimator:

\[
\hat{f}_2 = 50 \log \left( 1 + \frac{\sum_{i=1}^{p} (\bar{x}_{ri} - \bar{x}_{ti})^2}{p} \right)^{-1/2} \times 100.
\] (3)

\( \bar{x}_{ri} \) and \( \bar{x}_{ti} \) the experimentally observed means for the reference and tested products at time \( t_i \).

3. Results

To develop a solid oral form of 600 mg alpha-lipoic acid tablets, immediate-release, we have done the formula design, the Quality Target Product Profile, and subsequently tested the in vitro dissolution profiles of the selected formulas in comparison to the reference product in order to obtain a suitable, industrially scalable formula.

3.1. Preformulation Studies

Physico-Chemical Characterization

During the preformulation study, the reference listed drug (RLD) tablet’s physico-chemical characterization was done, and it is summarized in Table 2.

### Table 2. Physicochemical characterization of the reference listed drug (RLD) tablet (alpha-lipoic acid (ALA) 600 mg).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength/dose (mg)</td>
<td>600</td>
</tr>
<tr>
<td>Average weight (mg)</td>
<td>826.30</td>
</tr>
<tr>
<td>Coating</td>
<td>Film-coated tablets</td>
</tr>
<tr>
<td>Diameter (length/width/height) (mm)</td>
<td>oblong (19/9/6)</td>
</tr>
<tr>
<td>Hardness (N)</td>
<td>116</td>
</tr>
<tr>
<td>Friability</td>
<td>0.17%</td>
</tr>
<tr>
<td>Assay (% w/w of label claim)</td>
<td>102.79</td>
</tr>
</tbody>
</table>
Based on the characterization of the RLD, the Quality Target Product Profile (QTPP) was elaborated, and also the criteria for the product quality, safety, and efficacy of the targeted formulation were designed (Tables 3 and 4).

**Table 3.** Quality Target Product Profile (QTPP), designed criteria for the product, quality, safety, and efficacy of a specific product for the patient.

<table>
<thead>
<tr>
<th>QTPP</th>
<th>Target Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage form</td>
<td>Tablet, oblong, median line</td>
</tr>
<tr>
<td>Dosage design</td>
<td>Immediate release tablet no coating/film</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Oral</td>
</tr>
<tr>
<td>Dosage strength</td>
<td>600 mg</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>Immediate release enabling $T_{\text{max}}$ in two hours or less; bioequivalent to RLD</td>
</tr>
<tr>
<td>Stability</td>
<td>At least 24-month shelf-life at room temperature</td>
</tr>
</tbody>
</table>

**Table 4.** Drug product quality attributes according to QbD plan.

<table>
<thead>
<tr>
<th>QTPP</th>
<th>Target Parameters</th>
<th>Limits/Stipulations</th>
<th>Formula #3 (600 mg ALA)</th>
<th>Formula #4 (600 mg ALA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appearance</td>
<td></td>
<td>Conform</td>
<td>Conform</td>
<td></td>
</tr>
<tr>
<td>Odor</td>
<td>Characteristic</td>
<td>No unpleasant odor</td>
<td>No unpleasant odor</td>
<td></td>
</tr>
<tr>
<td>Friability, %</td>
<td>NMT 1.0</td>
<td>0.12</td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>Hardness, N</td>
<td>NLT 100</td>
<td>159</td>
<td>176</td>
<td></td>
</tr>
<tr>
<td>Drug product quality attributes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identification</td>
<td>The retention time of alpha-lipoic acid is similar to that of the main peak in the standard solution</td>
<td>Conform</td>
<td>Conform</td>
<td></td>
</tr>
<tr>
<td>Assay</td>
<td>600 mg ± 5%</td>
<td>602.80</td>
<td>612.20</td>
<td></td>
</tr>
<tr>
<td>Uniformity of dosage units</td>
<td>NMT 15</td>
<td>2.89</td>
<td>3.65</td>
<td></td>
</tr>
<tr>
<td>Dissolution, %</td>
<td>RLD: 77.0</td>
<td>55.9</td>
<td>67.2</td>
<td></td>
</tr>
<tr>
<td>Degradation by-products</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Residual solvents</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Water Content, %</td>
<td>NMT 10</td>
<td>2.01</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>Microbial limits</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total aerobic microbial count</td>
<td>Max. 104 UFC</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total yeast and molds count</td>
<td>Max. 102 UFC</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli/1 g</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td></td>
</tr>
</tbody>
</table>

Tests of compatibility between the raw materials were carried out. Critical Material Attributes (CMA) were established using quality risk management. Four formulation prototypes were prepared by direct compression, and its critical process parameters were defined using the design of experiment (DOE) approach (Table 5). As the compression force was identified as a critical process parameter influencing the following critical quality attributes: Hardness and dissolution, an acceptable range for compression force—were established.

**Table 5.** Critical process parameters for the direct compression stage.

<table>
<thead>
<tr>
<th>Critical Quality Attributes (CQA)</th>
<th>Critical Process Parameters (CPP)</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identity Assay</td>
<td>Compression speed</td>
<td>Low</td>
</tr>
<tr>
<td>Mass uniformity</td>
<td>Friability</td>
<td>Water content</td>
</tr>
<tr>
<td>Dissolution</td>
<td>Hardness</td>
<td>Compression force</td>
</tr>
</tbody>
</table>
3.2. Formulation Studies. Qualitative and Quantitative Formula Design

Alpha-lipoic acid was presented as a light yellow crystalline powder (Alpha-Lipoic Acid Powder, Fenchem Bioteck® Ltd., Nanjing, China). On a closer organoleptic examination, it was found that it has a slightly oily appearance.

After determining the type of alpha-lipoic acid used in the formulation, the appropriate excipients for developing the oral solid dosage form were chosen based on RLD labeling, literature, and reverse engineering (Table 2), according to the inactive ingredient database (IID) for FDA-approved oral solid dosage forms [88].

Carboxymethyl-cellulose sodium or Croscarmellose Sodium (CCS) is widely used in oral pharmaceutical formulations, primarily for its viscosity-increasing properties-adsorbent, emulsifying agent, super-disintegrant. In contact with water, it swells rapidly to about 4–8 times its original volume. As ALA is a BCS class II drug, rapid disintegration is necessary to ensure maximum bioavailability; it was used as a tablet binder at a 1–3% concentration. Grade C03 was selected.

Magnesium stearate is the most commonly used lubricant for tablets; it was added in the limits accepted by the European Pharmacopeia as a lubricant. It ensures the regular and equal filling of the compressing machine matrix, diminishing the adherence to the punch and the matrix during compression and supporting the tablet’s easy discharge. Their optimal concentration is 0.5–1.0%. This ratio ensures good lubrication and provides a suitable hardness, disintegration, and dissolution of the tablets.

Magnesium stearate is widely used as a pharmaceutical excipient and is generally regarded as nontoxic following oral administration [89]. Magnesium stearate grade E05 was selected of vegetable origin.

Silica colloidal anhydrus is used as a flowing agent due to the small size of its particles and greater specific surface, which improves the flowing properties of the mixture of ingredients. Its optimal concentration has proven to be 0.5%. It is a strong adsorbent and displays good stabilizing properties.

We tested two initial formulas based on the alpha-lipoic acid and excipients physico-chemical properties according to the design of experiments, Formula #1 and Formula #2 (Table 6).

Table 6. The initial experimental ALA oral tablet formulas-600 mg ALA (#1, #2).

<table>
<thead>
<tr>
<th>No.</th>
<th>Ingredient</th>
<th>Formula #1</th>
<th>Formula #2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Non-granulated ALA</td>
<td>97.5</td>
<td>97.5</td>
</tr>
<tr>
<td>2.</td>
<td>Sodium carboxymethylcellulose</td>
<td>1.5</td>
<td>1.0</td>
</tr>
<tr>
<td>3.</td>
<td>Magnesium stearate</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>4.</td>
<td>Colloidal silicon dioxide</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

The filling of the matrix was defective, the compression mixture stuck to the punches, the tablets’ appearance was not compliant (Figure 2), and the uniformity of the finished product’s mass varied above the accepted limit of 5% (Experimental formula #1 and #2).

![Figure 2](image-url)  
(a. Formula #1) (b. Formula #2)

Figure 2. Non-compliant tablets (Experimental formula (a) #1 and (b) #2).

From the technological processing point of view, the ALA powder had inappropriate rheological properties due to the fluffy consistency (bulk density: 0.354 g/mL), so it was not suitable for compression (Figure 3a). The first and second formulas were excluded...
because they were inappropriate due to high adhesion (stickiness). Thus, another type of alpha-lipoic acid was used, namely the granular one (Alpha-Lipoic Acid Powder, Fenchem Bioteck® Ltd., China) (Figure 3b).

![Figure 3. (a) Non-granulated alpha-lipoic acid active ingredient (b) granulated alpha-lipoic acid active ingredient.](image)

It no longer had an oily powder’s appearance, had a good flow (bulk density: 0.540 g/mL), the behavior towards the matrix and punches was improved (the tablets did not stick), not influencing the finished product’s dissolution profile (Experimental formula #3 and #4) (Table 7).

### Table 7. Comparison between the initial experimental ALA oral tablet formulas-600 mg ALA (#1, #2) and the adjusted ones (#3, #4).

<table>
<thead>
<tr>
<th>No.</th>
<th>Ingredient</th>
<th>Formula #1</th>
<th>Formula #2</th>
<th>Formula #3</th>
<th>Formula #4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>ALA</td>
<td>non-granulated</td>
<td>97.5</td>
<td>97.5</td>
<td>-</td>
</tr>
<tr>
<td>2.</td>
<td>Magnesium stearate</td>
<td>-</td>
<td>-</td>
<td>97.5</td>
<td>95.5</td>
</tr>
<tr>
<td>3.</td>
<td>Sodium Stearyl fumarate</td>
<td>0.5</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4.</td>
<td>Sodium Carboxymethylcellulose</td>
<td>1.5</td>
<td>1.0</td>
<td>1.5</td>
<td>3.0</td>
</tr>
<tr>
<td>5.</td>
<td>Colloidal silicon dioxide</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

The tablets obtained with Formula #3 had an improved appearance compared to the previous formulations, but again, after 20 min following the compression, the glue appeared on the back of the experimental Formula #3 tablet (Figure 4).

![Figure 4. Experimental formula #3-Non-compliant tablets-glue appeared on the backward after 20 min following the compression.](image)

3.2.1. Dissolution Profiles

Dissolution Profile of the Reference Listed Drug (RLD 600 mg)

Drug release is usually the rate-limiting process for absorption of a Biopharmaceutics Classification System (BCS) Class II compound like alpha lipoic acid due to its low solubility. Therefore, the dissolution of the RLD tablets was thoroughly evaluated. We tested the dissolution profile of the reference listed drug (Table 8, Figure 5).
Table 8. RLD dissolution profile in 900 mL dissolution medium using USP apparatus two at 75 rpm.

<table>
<thead>
<tr>
<th>Time (Min)</th>
<th>Reference Product Tablets/Percentage ofReleased ALA (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1  2  3  4  5  6  7  8  9  10  11  12  X*  ±SD**</td>
</tr>
<tr>
<td>5’</td>
<td>26.7 27.7 29.9 28.0 27.9 31.0 26.9 27.7 29.7 27.8 27.8 30.4 28.5 1.4</td>
</tr>
<tr>
<td>10’</td>
<td>39.3 41.0 41.7 43.4 40.3 40.8 38.7 40.5 41.4 42.9 40.4 40.4 40.9 1.3</td>
</tr>
<tr>
<td>15’</td>
<td>47.5 48.6 50.3 51.6 49.2 52.5 47.3 48.7 49.9 51.4 49.1 52.1 49.9 1.7</td>
</tr>
<tr>
<td>30’</td>
<td>61.9 62.6 63.9 66.3 63.1 65.6 61.2 62.5 63.8 66.2 63.0 65.2 63.8 1.7</td>
</tr>
<tr>
<td>45’</td>
<td>70.3 70.7 71.4 75.2 71.0 72.5 69.4 70.6 71.3 74.9 71.1 72.7 71.8 1.8</td>
</tr>
<tr>
<td>60’</td>
<td>75.7 76.6 77.2 78.6 76.0 77.5 75.7 76.9 77.1 78.5 75.8 77.9 77.0 1.0</td>
</tr>
</tbody>
</table>

* X—average, ** SD—standard deviation.

Figure 5. Reference listed formula initial dissolution profile (RLD Thiossen® 600 mg ALA).

Comparative Dissolution Profile of the Selected Formula #3 to RLD

We tested the dissolution profile on #3 Formula and calculated the similarity factor ($f_2$) compared to the reference listed product dissolution profile (Thiossen® 600 mg, Germany) (Table 9 and Figure 6).

Table 9. The dissolution profile of the Initial Formula #3–600 mg ALA in 900 mL of a medium using USP apparatus 2 at 75 rpm.

<table>
<thead>
<tr>
<th>Time (Min)</th>
<th>Tested Tablets (n) and the Amount of ALA Released in Time (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1  2  3  4  5  6  7  8  9  10  11  12  X*  SD*</td>
</tr>
<tr>
<td>5’</td>
<td>12.1 12.9 10.7 13.4 17.0 14.5 11.9 12.9 10.5 13.6 17.0 14.5 13.4 2.1</td>
</tr>
<tr>
<td>10’</td>
<td>15.8 17.9 15.7 17.6 20.4 19.8 15.8 18.0 15.7 17.9 20.6 19.6 17.9 1.9</td>
</tr>
<tr>
<td>15’</td>
<td>20.7 23.4 21.3 22.7 25.6 23.5 20.8 23.4 21.5 22.6 25.5 23.5 22.9 1.6</td>
</tr>
<tr>
<td>30’</td>
<td>32.5 38.4 34.8 35.4 37.6 38.9 32.6 38.4 34.9 35.5 37.4 39.0 36.3 2.3</td>
</tr>
<tr>
<td>45’</td>
<td>45.2 49.4 46.5 46.9 48.1 51.0 45.6 49.5 46.6 46.6 48.1 51.2 47.9 2.0</td>
</tr>
<tr>
<td>60’</td>
<td>53.7 57.4 54.9 56.0 56.2 57.5 53.6 56.7 55.0 56.0 56.1 57.5 55.9 1.3</td>
</tr>
</tbody>
</table>

* X—average, SD—standard deviation.
Table 10. Dissolution profile Test Formula #4–600 mg in 900 mL of medium (pH as shown) using USP apparatus 2 at 75 rpm.

<table>
<thead>
<tr>
<th>Time (Min)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>X</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>5′</td>
<td>21.7</td>
<td>23.2</td>
<td>22.3</td>
<td>22.9</td>
<td>25.6</td>
<td>23.5</td>
<td>22.2</td>
<td>23.4</td>
<td>22.5</td>
<td>22.6</td>
<td>26.0</td>
<td>23.5</td>
<td>23.3</td>
<td>1.2</td>
</tr>
<tr>
<td>10′</td>
<td>31.9</td>
<td>37.9</td>
<td>34.7</td>
<td>35.5</td>
<td>36.8</td>
<td>39.0</td>
<td>31.9</td>
<td>38.4</td>
<td>34.5</td>
<td>35.5</td>
<td>38.0</td>
<td>38.9</td>
<td>36.1</td>
<td>1.5</td>
</tr>
<tr>
<td>15′</td>
<td>45.3</td>
<td>48.4</td>
<td>46.7</td>
<td>47.2</td>
<td>48.1</td>
<td>51.1</td>
<td>46.2</td>
<td>50.2</td>
<td>46.8</td>
<td>46.9</td>
<td>49.0</td>
<td>51.2</td>
<td>48.1</td>
<td>1.1</td>
</tr>
<tr>
<td>30′</td>
<td>53.8</td>
<td>57.5</td>
<td>55.9</td>
<td>56.9</td>
<td>57.2</td>
<td>58.2</td>
<td>55.6</td>
<td>57.3</td>
<td>56.5</td>
<td>56.1</td>
<td>56.5</td>
<td>60.1</td>
<td>56.8</td>
<td>1.4</td>
</tr>
<tr>
<td>45′</td>
<td>65.2</td>
<td>69.4</td>
<td>66.5</td>
<td>66.1</td>
<td>58.1</td>
<td>61.9</td>
<td>64.6</td>
<td>59.5</td>
<td>66.6</td>
<td>62.6</td>
<td>58.1</td>
<td>61.2</td>
<td>63.3</td>
<td>1.4</td>
</tr>
<tr>
<td>60′</td>
<td>69.7</td>
<td>71.4</td>
<td>70.9</td>
<td>72.1</td>
<td>61.2</td>
<td>67.5</td>
<td>69.6</td>
<td>62.7</td>
<td>72.0</td>
<td>63.8</td>
<td>62.1</td>
<td>63.5</td>
<td>67.2</td>
<td>1.3</td>
</tr>
</tbody>
</table>

* X—average, SD—standard deviation.

Figure 6. Comparative profile Test Formula #3 (Thioalpha 600 mg ALA)-Reference listed Formula (Thiossen® 600 mg ALA).

Dissolution Profile of Test Formula #4

To improve the technological compliance, dissolution profile, and similarity factor, we increased sodium stearyl fumarate and croscarmellose sodium content and developed formula #4 (Table 2).

We tested the dissolution profile on #4 Formula and calculated the similarity factor ($f_2$) compared to the reference listed product dissolution profile (Thiossen® 600 mg, Germany) (Table 10 and Figure 7).

Table 7. The dissolution profile of the Initial Formula #3–600 mg ALA in 900 mL of medium (pH as shown) using USP apparatus 2 at 75 rpm.

<table>
<thead>
<tr>
<th>Time (Min)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>X</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>5′</td>
<td>21.7</td>
<td>23.2</td>
<td>22.3</td>
<td>22.9</td>
<td>25.6</td>
<td>23.5</td>
<td>22.2</td>
<td>23.4</td>
<td>22.5</td>
<td>22.6</td>
<td>26.0</td>
<td>23.5</td>
<td>23.3</td>
<td>1.2</td>
</tr>
<tr>
<td>10′</td>
<td>31.9</td>
<td>37.9</td>
<td>34.7</td>
<td>35.5</td>
<td>36.8</td>
<td>39.0</td>
<td>31.9</td>
<td>38.4</td>
<td>34.5</td>
<td>35.5</td>
<td>38.0</td>
<td>38.9</td>
<td>36.1</td>
<td>1.5</td>
</tr>
<tr>
<td>15′</td>
<td>45.3</td>
<td>48.4</td>
<td>46.7</td>
<td>47.2</td>
<td>48.1</td>
<td>51.1</td>
<td>46.2</td>
<td>50.2</td>
<td>46.8</td>
<td>46.9</td>
<td>49.0</td>
<td>51.2</td>
<td>48.1</td>
<td>1.1</td>
</tr>
<tr>
<td>30′</td>
<td>53.8</td>
<td>57.5</td>
<td>55.9</td>
<td>56.9</td>
<td>57.2</td>
<td>58.2</td>
<td>55.6</td>
<td>57.3</td>
<td>56.5</td>
<td>56.1</td>
<td>56.5</td>
<td>60.1</td>
<td>56.8</td>
<td>1.4</td>
</tr>
<tr>
<td>45′</td>
<td>65.2</td>
<td>69.4</td>
<td>66.5</td>
<td>66.1</td>
<td>58.1</td>
<td>61.9</td>
<td>64.6</td>
<td>59.5</td>
<td>66.6</td>
<td>62.6</td>
<td>58.1</td>
<td>61.2</td>
<td>63.3</td>
<td>1.4</td>
</tr>
<tr>
<td>60′</td>
<td>69.7</td>
<td>71.4</td>
<td>70.9</td>
<td>72.1</td>
<td>61.2</td>
<td>67.5</td>
<td>69.6</td>
<td>62.7</td>
<td>72.0</td>
<td>63.8</td>
<td>62.1</td>
<td>63.5</td>
<td>67.2</td>
<td>1.3</td>
</tr>
</tbody>
</table>

* X—average, SD—standard deviation.

Figure 7. Comparative profile Test formula #4 (600 mg ALA)-blue versus Reference Listed Drug (600 mg ALA)-orange.
3.2.2. Quality Profile of the Tested Formula #3, #4 vs. RLD

The two formulations (Test #3, Test #4, and RLD) were subjected to quality and quantity control, evaluating the pharmaco-technical properties (Table 11).

<table>
<thead>
<tr>
<th>Product</th>
<th>Average Tablet Mass (mg) SD (± %)</th>
<th>Hardness (N) NLT 100</th>
<th>Friability (%) NMT 1</th>
<th>Concentration of Alpha-Lipoic Acid (mg/tablet)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Formula #3 600 mg S570317/Exp. 03.2019</td>
<td>623.90 −1.1/+1.14</td>
<td>159</td>
<td>0.12</td>
<td>602.80</td>
</tr>
<tr>
<td>Test Formula #4 600 mg S580317/Exp. 03.2019</td>
<td>623.4 −1.42/+1.24</td>
<td>176</td>
<td>0.15</td>
<td>612.20</td>
</tr>
<tr>
<td>Reference Product 600 mg S: 17D029/Exp. 03.2022</td>
<td>826.3 −1.03/+0.88</td>
<td>116</td>
<td>0.17</td>
<td>616.74</td>
</tr>
</tbody>
</table>

The quality of the obtained ALA FSP was found to be similar to that of the RLD by testing the following parameters: Average tablet mass, Hardness, Friability, Assay of alpha-lipoic acid (mg/tablet), and Dissolution.

3.3. Chromatographic Analysis. Validation of the Chromatographic Method

3.3.1. The Stability and Performance of the Chromatographic System (System Suitability)

We tested the chromatographic system’s reliability by multiple injections (n = 6) of the standard solution=1,024 mg/mL alpha-lipoic acid in the dilution solvent (Figure 8). We evaluated the following parameters: (a) Retention time (t); (b) Number of theoretical plates (N); (c) Asymmetry factor (T); (d) System repeatability-RSD <2% (retention time, peak area) (Table 12).

Figure 8. Testing of system suitability (n = 6, overlay chromatograms).
Table 12. System performance characterization parameters (retention time, peak height, area, Wh/2, asymmetry factor, and theoretical plates).

<table>
<thead>
<tr>
<th>Samples of the Alpha-Lipoic Acid Standard Solution</th>
<th>T (min)</th>
<th>H (µV)</th>
<th>A (µV × s)</th>
<th>Wh/2, (min)</th>
<th>Asymmetry Factor (T)</th>
<th>Theoretical Plates (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>4.90</td>
<td>810,256</td>
<td>7,899,718</td>
<td>0.135</td>
<td>1.56</td>
<td>7333</td>
</tr>
<tr>
<td>2.</td>
<td>4.89</td>
<td>812,991</td>
<td>7,915,821</td>
<td>0.135</td>
<td>1.56</td>
<td>7326</td>
</tr>
<tr>
<td>3.</td>
<td>4.89</td>
<td>813,739</td>
<td>7,915,642</td>
<td>0.134</td>
<td>1.56</td>
<td>7335</td>
</tr>
<tr>
<td>4.</td>
<td>4.89</td>
<td>813,211</td>
<td>7,914,573</td>
<td>0.134</td>
<td>1.56</td>
<td>7338</td>
</tr>
<tr>
<td>5.</td>
<td>4.89</td>
<td>814,106</td>
<td>7,913,492</td>
<td>0.134</td>
<td>1.56</td>
<td>7334</td>
</tr>
<tr>
<td>6.</td>
<td>4.89</td>
<td>815,434</td>
<td>7,927,189</td>
<td>0.134</td>
<td>1.56</td>
<td>7340</td>
</tr>
<tr>
<td>X</td>
<td>4.89</td>
<td>813,290</td>
<td>7,914,406</td>
<td>0.134</td>
<td>1.56</td>
<td>7334</td>
</tr>
<tr>
<td>SD</td>
<td>0.003</td>
<td>1568.8</td>
<td>7995.1</td>
<td>0.0</td>
<td>0.002</td>
<td>4.42</td>
</tr>
<tr>
<td>RSD</td>
<td>0.07</td>
<td>0.21</td>
<td>0.11</td>
<td>0.087</td>
<td>0.17</td>
<td>0.07</td>
</tr>
</tbody>
</table>

n = number of injections, X—average, SD—standard deviation; RSD—relative standard deviation (%).

3.3.2. Selectivity and Specificity of the Method

We tested the selectivity and specificity of the method regarding the influence of the extraction solvent, mobile phase, and excipients in the product composition (placebo, Figure 9a). As ALA retention time was 4.9 min for a standard solution (Figure 9b), for reconstituted 600 mg ALA sample solutions (Figure 9c) and also for tested formula #4 solution (Figure 9d) and no peak was seen in the solvent, mobile phase or placebo solution chromatograms at 4.9 min, the selectivity of the method was demonstrated.

Figure 9. (a) The chromatogram of the placebo solution, (b) The chromatogram of the alpha-lipoic acid standard solution 1.024 mg/mL (c) The chromatogram of the reconstituted 600 mg ALA sample solutions (d) The chromatogram of the tested formula #4 solution 600 mg- tablets (batch no. S580317).
4. Discussion

The recent literature shows continuous research on improving the BCS class II ALA biodisponibility through formulation adjustments to achieve a higher bioavailability ($C_{\text{max}}$ and AUC values) and decreased time to maximum concentration ($T_{\text{max}}$) and $T_{1/2}$. This goal is achieved by several approaches, using the natural stereoisomer R-lipoic acid (RLA) and the sodium salt (NaRLA), complexation with octenylsuccinylated high-amylose starch [90]; by encapsulation and stabilization in cyclodextrin inclusion complex [91], incorporation in natural polysaccharide-based gel beads [92], cyclodextrin inclusion complex electrospun nanofibers [93] and others; Nevertheless these forms are under development and not available in the current therapy.

Conventional release ALA racemic solid oral forms are used in therapy, both as medicines and as food supplements or vitamin mixes; the previous study showed that the standards of industrial manufactured ALA-based supplements concentration ranged from 97.8 to 104.1% and for manipulated capsules concentration ranged from 69.2 to 95.4%, a great variability [90]. However, a QbD approach in developing the commercial forms of ALA is seldom used and can assure an optimal formulation and a biodisponibility comparable to RLD even for FSP or vitamin mixes.

Our study approaches the ALA formulation by assessing the preformulation parameters, the critical quality attributes in order to obtain a FSP with a dissolution profile similar to the reference listed drug (RLD) according to the USP.

US FDA Guidance describes the model-independent mathematical approach proposed by Moore and Flanner for calculating a similarity factor ($f_2$) of dissolution testing of immediate-release solid oral dosage forms describes that drug dissolution may be the rate-limiting step for drug absorption in the case of low solubility/high permeability drugs (BCS class II drugs).

We used the USP method using 900 mL water dissolution medium, in USP apparatus 2, stirred one hour at 75 rpm. This method is capable of differentiating between the manufactured formulations and RLD.

The similarity factor $f_2$, which defines the distance between the dissolution curves for two tested products, was estimated [90]. The similarity factor ($f_2$) is 100 when the difference between reference and test formulation is insignificant. Literature studies and current quality guidelines consider that a value of the $f_2$ factor greater than 50 signifies “less than 10% difference” between profiles and is accepted as a similarity between dissolution profiles.

The similarity factor of Test Formula #3–600 mg, and the reference product (RLD) was $f_2 = 31.6$, below 50.

The similarity factor of Test Formula #4–600 mg, and the reference product (RLD) was $f_2 = 58.5$.

The obtained $f_2$ value of 31.6 for Test Formula #3, compared with the reference product, is below the desired limit, so the formulation will show a weak in vivo performance, not being suitable for therapeutic use. In case of the Test Formula #4, $f_2$ has a value over the minimum required limit meaning the obtained tablets have a similar dissolution profile, but the value is still not close to 100, showing that the two compared products achieve different dissolution rate, which can lead to significant in vivo differences.

The parameters that define the HPLC peaks (retention time, height, area, peak width at half height) and system performance parameters (asymmetry factor, number of theoretical plates) are reproducible. The relative standard deviation was below 2% (for time retention area, peak area), demonstrating that the system is stable and efficient, corresponding to the proposed purpose (Figure 8, Table 12). Also, the chromatograms showed that placebo has no signals at the retention time of alpha-lipoic acid, so the method is selective against placebo; thus, the excipients do not interfere with the HPLC determination (Figure 9).

5. Conclusions

In order to develop a product based on alpha-lipoic acid, a micronutrient with several pharmacological as well as antioxidant properties, in a concentration of 600 mg per tablet,
with oral administration and immediate release, we have performed the pharmaceutical development taking into account technological and dissolution aspects—compared to the reference listed drug (RLD).

The present research started with the preformulation studies on the active ingredient physical properties according to the Quality Target Product Profile (QTPP) defined based on the properties of the drug substance, characterization of the RLD product, and consideration of the RLD label. Identification of critical quality attributes (CQAs) targeted the drug bioavailability not to fail the reference drug product; and included assay, mass uniformity, hardness, friability, and dissolution.

A design of experiment (DOE) was conducted to identify the critical material attributes (CMA), showing that the granular form of ALA is more suitable to be processed under solid dosage forms than the powdered one that led to sticking materials and patchy tablets.

The second design of the experiment (DOE) was conducted to identify the critical process parameters (CPP); it showed that a strong compression force could negatively impact the critical quality attributes of the formulation like hardness and dissolution; thus, an acceptable range for compression force was established.

The formulation studies led to four final powder formulas that presented a good flowability, considered adequate for the direct compression process. After the materials were compacted, we could notice that the first two formulas drove to improper nonhomogeneous tablets, being excluded from the following tests.

The other two formulations (Test #3 and Test #4) were subjected to quality and quantity control, evaluating the pharmaco-technical properties, dissolution rates, and assay. In terms of physical characteristics, the fourth formulation leads to good mechanical resistance, low friability, and excellent mass uniformity compared to the third formulation and comparable qualities as the reference product.

ALA is a poorly soluble, highly permeable Biopharmaceutics Classification System (BCS) Class II compound. Consequently, we focused on predicting in vivo performance using a dissolution method. The developed alpha-lipoic acid 600 formulation (Test #4) is characterized by a dissolution rate similar to the reference product. The release is de facto a slow-release, the value obtained after 60 min not being a saturation value, neither in the test product nor in the reference one.

The analytical variability between the same series’s tablets is low, less than 4%, which proves the uniformity of dissolution rate in the same batch.

The dissolution rate for Test #4 formulation is higher than Test #3 formulation due to the presence of a greater amount of sodium carboxymethylcellulose used, its disintegrant properties being well known.

Also, in the release of ALA from the solid dosage forms, the direct compression method played an important role, by all its advantages, shortening the time needed for disintegration.

A simple quantitative formula is not enough to assure good ALA bioavailability; the formulation needs multiple compounding modulations under physicochemical compatibility algorithms, with multiple dissolution profiles testing back-ups. It is essential to ensure a formulation with an in vitro dissolution comparable with the RLD, allowing the compound to reach its target level to assure the optimum claimed antioxidant activity of ALA at the cellular level, even for food supplement formulations.
Supplementary Materials: The following are available online at https://www.mdpi.com/2227-9717/9/1/176/s1, Table S1. Characteristic of ingredients used in the studies.


Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The authors extend their gratitude to AC HELCOR R&D Center for providing reference and experimental formulation samples and different testing facilities.

Conflicts of Interest: The authors declare no conflict of interest regarding this paper’s publication.

Abbreviations

ALA Alpha-lipoic acid
AOX Antioxidant
ADAM17 ADAM metalloprotease domain 17
AOPP Advanced Oxidation Protein Products
AON Acute Optic Neuritis
BCS Biopharmaceutics Classification System
Bcl-xL B-cell lymphoma-extra large
CI Confidence Interval
CMA Critical Material Attributes
CQAs Critical Quality Attributes
CCS Croscarmellose Sodium
CFTR Cystic-fibrosis-transmembrane-conductance-regulator
CRP C-Reactive protein
DOE Design of Experiments
EU European Union
FDA Food Drug Administration
HPLC High-Performance Liquid Chromatography
HMGBl High-mobility-group-box-1
IID Inactive Ingredient Database
IL-6 Interleukin 6
FSP Food Supplement Products
MetS Metabolic Syndrome
Mcl-1 Myeloid leukemia cell differentiation protein
MGMT O 6-methylguanine-DNA methyltransferase
NSAIDs Non-steroidal anti-inflammatory drugs
NADPH Nicotinamide adenine dinucleotide
OCT optical coherence tomography
PCOS polycystic ovary syndrome
PSD Particle Size Distributions
RLD Reference Listed Drug
R&D Research and Development
RPM Rotation per minute
References


11. Xiong, Y.; Yin, Q.; Li, J.; He, S. Oxidative Stress and Endoplasmic Reticulum Stress Are Involved in the Protective Effect of Alpha Lipoic Acid Against Heat Damage in Chicken Testes. Animals 2020, 10, 384. [CrossRef]


78. McCarty, M.F.; DiNicolantonio, J.J. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. Prog. Cardiovasc. Dis. 2020. [CrossRef]


